Eli Lilly | LLY - Interest Income


Eli Lilly reported $65M in Interest Income for its fiscal quarter ending in September of 2025.





Interest Income Change Date
AbbVie USD 72M 13M Mar/2026
Abbott USD 106M 28M Mar/2026
ALKERMES USD 8.54M 3.59M Mar/2026
AstraZeneca USD 80M 7M Jun/2026
Baxter International USD 12M 1000K Mar/2026
Biogen USD 37.9M 700K Mar/2026
Drreddys Laboratories INR 796M 332M Dec/2025
Eli Lilly USD 65M 25M Sep/2025
Gilead Sciences USD 95M 0 Mar/2026
GlaxoSmithKline GBP 22M 96M Mar/2026
Glaxosmithkline GBP 22M 4M Mar/2026
J&J USD 2.27 0.13 Jun/2026
Medtronic USD 114M 23M Jan/2025
Merck USD 35M 34M Mar/2026
Pfizer USD -0.04 115M Jun/2026
Phibro Animal Health USD 0.08 0.09 Dec/2024
Regeneron Pharmaceuticals USD 183.3M 200K Jun/2026
Sanofi EUR 77M 17M Jun/2026
Sanofi EUR 60M 54M Mar/2026
United Therapeutics USD 31.5M 10.3M Jun/2026
Zoetis USD 25M 1000K Dec/2025